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rived from the 3 phase III clinical trials of tapentadol PR in osteoarthritis and lower
back pain and published literature. Switch rates to 2nd line therapies and co-
medication costs were provided by the National Centre of Pharmacoeconomics
based on the GMS database analysis. Costs of physician visits were obtained by
applying local costs to the number of physician visits in each therapy line obtained
from a retrospective analysis of the UK THIN database of GP patient records. One-
way deterministic and probabilistic sensitivity analyses were undertaken to assess
the impact of parameter uncertainty. RESULTS: Mean annual total costs per pa-
tient from GMS Scheme perspective amount to 4,367€ for tapentadol vs. 4,381€ for
oxycodone. Tapentadol generates 0.6316 QALYs compared to 0.6122 QALYs for
oxycodone, resulting in tapentadol being a dominant treatment. For DP/LTI
Scheme, tapentadol had an ICER of 1,662 €/QALY gained. Results were robust in a
broad range of sensitivity analyses. Probability that tapentadol is cost-effective vs.
oxycodone at threshold of 20,000 €/QALY gained exceeded 95%. CONCLUSIONS:
Compared to oxycodone CR, the most commonly used oral drug for chronic severe
non-cancer pain in Ireland, tapentadol PR appears to be a highly cost-effective
treatment option.
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OBJECTIVES:To assess the cost-effectiveness of tapentadol PR compared to opioids
(morphine, oxycodone, transdermal buprenorphine [TDB] and transdermal fenta-
nyl [TDF]) for the treatment of severe chronic non-cancer pain from the societal
perspective in Portugal. METHODS: A one year Markov transition state model with
monthly cycles was built. Four health states were defined: ‘no withdrawal and no
adverse events treated’, ’occurrence of adverse events (AEs) with need for medical
treatment’, ’withdrawal due to AEs’, and ‘withdrawal due to lack of efficacy’. If
patients did not adequately respond to treatment or withdraw, switching to alter-
native second line opioid (morphine, hydromorphone, TDB or TDF) was consid-
ered. Third line therapy was the absorption state. Data regarding efficacy, tolera-
bility and utility values (EQ-5D) were derived from clinical trials and published
literature. Switch rates to subsequent opioid therapies and resource consumption
were estimated by clinical experts. Costs were calculated from the societal per-
spective. Direct costs were calculated based on official Portuguese prices/tariffs,
indirect costs derived from the National Health Survey. One-way and probabilistic
sensitivity analyses were conducted. RESULTS:Mean annual total costs per patient
amounted to 3793 € for morphine, 3,804€ for TDF, 3891 € for TDB, 3964 € for oxy-
codone, and 4117 € for tapentadol. Total QALYs generated were 0.6102 (morphine),
0.6062 (TDF), 0.6026 (TDB), 0.6096 (oxycodone), and 0.6287 (tapentadol). The result-
ing ICERs (€/QALY gained) for tapentadol yield 7,995 versus oxycodone, 8,685 versus
TDB, 13,943 versus TDF, and 17,547 versus morphine. Varying costs, probabilities,
and utilities by 50%, 10%, and 10%, respectively, resulted in an ICER range
from tapentadol being dominant (vs. oxycodone) to 26,000 €/QALY gained (vs.
morphine). CONCLUSIONS: To improve pain relief and quality of life in patients
with severe chronic pain tapentadol appears to be the favourable and cost-effective
treatment option from the societal perspective in Portugal.
PSY33
CLINICAL AND ECONOMIC ANALYSIS OF ELTROMBOPAG IN CHRONIC
IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CONTEXT OF RUSSIAN
HEALTH CARE SYSTEM
Vorobyev PA1, Krasnova L2, Borisenko O1
1Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia, 2Moscow
State Medical University named after I.M.Sechenov, Moscow, Russia
OBJECTIVES: The emergence of new drugs for the treatment of patients with
chronic idiopathic thrombocytopenic purpura (ITP), stimulates the proliferation of
megakaryocyte germ (eltrombopag), stresses the need to conduct a comparative
analysis in their cost-effectiveness, compared with other modern treatment
options. METHODS: Markov modeling was used. Markov model, developed by
GlaxoSmithKline, was adapted to the context of Russian health care system to
assess cost-utility and cost-effectiveness of eltrombopag and romiplostim for
treatment of chronic ITP in patients, for whom splenectomy is contradicted. El-
trombopag and romiplostim were used as first-line options. The simulation was
performed taking into account the time perspective for 2 years, 10 and 20 years.
Data about diagnosis and treatment of ITP in “real world” settings was collected by
interviewing 5 expert-hematologists with expertise in the treatment of chronic ITP,
working in different health facilities in Russia. Only direct medical costs were
calculated. RESULTS: Cost-effectiveness ratio for criterion “additional years of life”
after 2 years of onset was $27,703 for eltrombopag and $31,988 for romiplastim,
after 10 years of onset – $21,758 and $24,700 respectively, after 20 years of onset –
$17,257 and $19,577 respectively. Cost of QALY after 2 years of onset was $39,000 for
eltrombopag and $45,530 for romiplastim, after 10 years of onset – $35,108 and
$40,218 respectively, after 20 years of onset – $32 527 and $37,204 respectively.
CONCLUSIONS: Eltrombopag is cost-effective compared with romiplostim as a
first-line therapy in treatment of chronic idiopathic thrombocytopenic purpura in
patients, for whom splenectomy is contradicted.
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OBJECTIVES: To conduct an economic evaluation comparing, ferinject (Ferric Car-
boxymaltose) with Venofer (iron sucrose), iron sucrose similars (ISS-generic forms
of iron sucrose) and Cosmofer (low molecular weight-LMW iron dextran) in the
management of anaemia patients in Greece.METHODS:A cost-minimization anal-
ysis, from National Health System (NHS) perspective, was conducted since there
are no clear data indicating that one of these regimens is superior to the others in
terms of efficacy. Because iron could be administered either to inpatients (i.e.,
surgical patients or patients hospitalized due to a disease related to chronic or
acute blood loss) or to outpatients (i.e. non-dialysis chronic kidney disease patients
etc), the economic evaluation was undertaken for these two large categories of
patients, separately. Total cost related to each treatment includes the cost of drugs,
the cost of disposables for each infusion, the monitoring cost during infusion (sal-
aries of personnel), the cost for management of adverse events, the cost of visits,
the productivity loss, and the travelling cost of patients. A supplementary budget
impact analysis was also conducted. RESULTS: The mean total (direct) cost of
therapy with Ferric Carboxymaltose was €216.32, in the iron sucrose arm the cost
was €296.34, in the LMW iron dextran arm was €251.12, while in the ISS the cost was
estimated at €324.47 for inpatients. In the case of outpatients the cost of ferric
carboxymaltose was €152.66, the cost of iron sucrose was €285.10, the cost of LMW
iron dextran was €459.88 and the cost of ISS was estimated at €313.13. Various
sensitivity analyses showed that the main results were robust, reaching a statisti-
cal significant difference in 95% level of significance. CONCLUSIONS: Ferric Car-
boxymaltose represents a cost-saving option compared with other alternative
therapies used in the management of anaemia in the National Health Service of
Greece.
PSY35
ECONOMIC EVALUATION OF DARBEPOETIN ALFA IN THE MANAGEMENT OF
END STAGE RENAL DISEASE (ESRD) PATIENTS WITH ANEMIA IN THE GREEK
NHS SETTING
Fragoulakis V1, Iatrou C2, Maniadakis N1
1National School of Public Health, Athens, Greece, 2General Hospital of Nikaia, Athens, Greece
OBJECTIVES: To conduct an economic evaluation for End Stage Renal Disease
(ESRD) diabetic and non diabetic patients treated with Darbepoetin alfa, Epoetin
alfa, Epoetin beta and Epoetin Beta (Methoxy polyetylene Glycol). METHODS: A
cost-minimization analysis was conducted since there are no clear data indicating
differences in terms of efficacy. A probabilistic Markov model was constructed to
simulate during a 20-year time span the progress of patients through four health
states: “dialysis”, “transplantation”, “dialysis after graft failure” and “death”. The
dose required to maintain the desirable Hb level (10 – 12 g/dL) was obtained from
the literature alongside transition probabilities for the baseline cohort (mean age
65, diabetics 54%). Costs were estimated from the perspective of the healthcare
system and reflect the drug administration, the monitoring of patients, transplan-
tations and other resources consumed by patients valued at €2011. A 3.5% discount
rate was used for outcomes. RESULTS: The mean survival (common for all com-
parators) expressed in terms of QALY’s was 2.16 (95%Uncertainty Interval (UI):
2.11-2.21) overall, and 2.23 (95%UI: 2.18-2.29) and 2.10 (95%UI: 2.05-2.14) for patients
without and with diabetes, respectively. The mean total treatment cost for patients
on Darbepoetin alfa was 11,505 (95%UI: €11,322-€11,680) for the entire population,
€11,103 (95%UI: €10,906-€11,299) for diabetic and €11,976 (95%UI: €11,739-€12,197)
for non-diabetic patients. The mean cost of patients on Epoetin alfa was €15,340
(95%UI: €15,118-€15,554), €14,720 (95%UI: €14,466-€14,976), and €16,068 (95%UI:
€15,760-€16,343) respectively. The cost of Epoetin beta was €15,038 (95%UI: €14,783-
€15,292), €14,435 (95%UI: €14,160-€14,707) and €15,746 (95%UI: €15,434-€16,063) re-
spectively. Finally, for patients on Epoetin Beta (Methoxy polyetylene Glycol), it was
€12,057 (95%UI: €11,868-€12,238), €11,624 (95%UI: €11,416-€11,823) and €12,566
(95%UI: €12,320-€12,796) respectively. CONCLUSIONS:Darbepoetin alfa (AranespÒ)
may represent a cost saving option, compared to other alternative therapies used
in the management of ESRD patients in the National Health Service of Greece.
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OBJECTIVES: Obesity represents a considerable and increasing health problem.
The objective of this research was to assess the clinical and cost-effectiveness of
orlistat in overweight and obese patients in primary care. METHODS: A cohort
simulation model was built in Simul8 to explore the potential benefits of treatment
with orlistat compared with standard care. The model used a lifetime horizon to
estimate the incremental cost per quality adjusted life-year (QALY) gained. Clinical
effectiveness was modelled using the results of a mixed treatment comparison.
Longitudinal analyses of the General Practice Research Database (n100,000) were
used to derive BMI related estimates for times to death, primary myocardial infarc-
tion or stroke, onset of type 2 diabetes, and to estimate the natural history of body
mass index (BMI) in people who are obese. Annual probabilities of subsequent
cardiovascular events were estimated using data from the Nottingham Heart At-
tack register and South London Stroke register. Health related quality of life values
were modelled using a relationship between BMI and EQ-5D data controlling for age
an comorbidities. Current event and post-event health states were used to incor-
porate changes in health related quality of life and costs. RESULTS: Deterministic
analysis gave a cost per QALY gained (versus placebo) of £1,665, although this figure
is sensitive to the baseline BMI, due to the strong correlation of BMI and the risk of
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CV events and T2DM. CONCLUSIONS: Orlistat is a cost-effective treatment to aid
weight reduction in primary care when using a threshold of £20,000 per QALY.
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OBJECTIVES: As part of a medico-economic study on a fibrin sealant used in ortho-
pedic surgery to decrease allogeneic transfusion requirement, this study was con-
ducted to evaluate the overall cost of transfusion from hospital perspective.
METHODS:A multicenter prospective study was carried out from March 14, 2011 to
June 1, 2011 in orthopedic surgery wards of 3 French university hospitals. A micro-
costing has been developed to identify global costs of transfusion through: the
acquisition cost of red blood cell (RBC), supplies used for a transfusion, and times
spent by medical and nurse staff for the management of the transfusion timed by
a pharmacy resident with a stopwatch. Corresponding costs for staff were esti-
mated from mean salaries for medical and non medical staff in 2011.RESULTS: Five
transfusions were observed in each site. A physician spent 1’01” 43” (mean 
standard deviation) for the prescription of RBC. Personal care assistants and hos-
pital workers brought samples to the Blood Bank (BB), transmitted the document to
the BB, and delivered RBC to the ward which took 10’17” 05’46” and 10’47” 03’20”
respectively. Nurses spent 52’23” 04’39” for the control of the documents, the
ultimate pre-transfusion control at patient’s bedside, the administration of RBC
and the monitoring of the transfusion. No adverse event occurred during the study.
The mean global cost of the transfusion of a RBC was estimated at 254 Euros.
Regarding global cost, management of transfusion was estimated at 31 Euros rep-
resenting 12% of the overall cost of transfusion. CONCLUSIONS: The study shows
the heavy workload represented by each transfusion for a nurse in the context of
shortage of nurses. These results may be helpful to fill a pharmacoeconomic model
used to estimate the incremental cost effective of using fibrin sealant in orthopedic
surgery.
Systemic Disorders/Conditions – Patient-Reported Outcomes & Preference-Based
Studies
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OBJECTIVES: Evaluate the relative impact of migraine-related outcomes using gen-
eralized healthy-time equivalences (HTE). METHODS: A best-practice conjoint
analysis or discrete-choice experiment (DCE) evaluated migraine-related outcomes
reported in the Completeness of Response Survey (CORS). We elicited patients’
trade-off preferences for migraine symptoms with different clinically relevant du-
rations, including symptom-free time. Preference-parameter estimates were used
to determine the amount of symptom-free time that was utility-equivalent to 24-
hour migraine episode profiles described by acute headache, post-headache, and
symptom-free phases. These HTEs quantify the impact of migraine-related out-
comes using a fully general utility-theoretic conceptual framework. Unlike quality-
adjusted life years (QALYs), HTEs do not require assuming that utility of a brief, but
severe, outcome is a simple fraction of a quality-adjusted year. Also unlike QALYs,
HTEs do not require risk neutrality, and easily account for personal characteristics
that may determine preferences for health outcomes. RESULTS: A total of 539
people with a self-reported physician diagnosis of migraine completed the survey.
As expected, migraineurs were negatively affected by the duration of headache-
phase and post-headache-phase symptoms. However, for some groups in the sam-
ple we found no statistical difference in relative preferences for different pain
severities in the acute headache phase. Subjects had clear preferences for different
levels of daily-activity limitations experienced during the post-headache phase.
Results also showed that subjects in the sample were averse to risk. We also found
preference heterogeneity based on individual characteristics. CONCLUSIONS: This
study demonstrates the feasibility of obtaining standardized healthy-time equiv-
alences derived from clinically-relevant symptom-duration tradeoff data as a fea-
sible alternative to QALYs for acute, self-limiting conditions. The results also sug-
gest that the assumptions associated with the use of conventional QALYs are not
met by our sample of migraineurs; adding to the mounting body of evidence that
encourages the use of more flexible utility-theoretic measures of quality-adjusted
time.
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OBJECTIVES: Previous studies have examined the humanistic burden of rheuma-
toid arthritis; however, less research has been conducted to understand the factors
that are most strongly associated with the health-related quality of life of these
patients. METHODS: Data from the European 2010 National Health and Wellness
Survey (an annual survey of respondents from France, Germany, Italy, Spain, and
the UK) were used in the current study. Only respondents who reported being
diagnosed with RA (N498) were included in the analyses. Health state utilities
(SF-6D), derived from the SF-12, were examined on a bivariate level across a variety
of subgroups (e.g., years diagnosed, treatment status, comorbidities, joints af-
fected, etc). Health state utilities were also predicted from demographic and pa-
tient characteristic information using multiple regressions. RESULTS:A total of 498
patients (0.86%) reported being diagnosed with RA. These patients were mostly
female (64.3%) and had an average age of 52.3 years. Most patients were diagnosed
with RA for more than 10 years (55.8%). Several demographic and patient charac-
teristic factors were significantly associated with health state utilities. RA patients
in Spain (Adjusted Mean0.60) and Italy (Adjusted mean0.53) had the highest and
lowest, respectively, utility scores. Severe RA (Adjusted mean0.51), comorbid
Crohn’s disease (Adjusted mean0.52), and RA affecting the spine (Adjusted
mean0.54) were associated with the largest decrements in utility scores (all
ps.05). CONCLUSIONS: Although previous studies have documented the burden
of RA in Europe, the current study suggests that burden is not uniform. Certain
geographies, particularly Italy, are associated with a greater burden for patients
with RA. Similarly, patient characteristics, such as arthritis of the spine and comor-
bid Crohn’s disease, have a large effect on the quality of life of these patients. These
results suggest a more comprehensive assessment of patient characteristics is
necessary to fully capture the quality of life burden of RA.
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OBJECTIVES: To analyze QoL of patients with chronic pain due to osteoarthritis of
the knee (OA) or low back pain (LBP) using the EQ-5D questionnaire in phase III
trials with tapentadol prolonged release (PR) and oxycodone controlled release
(CR).METHODS: Three phase III trials in OA and LBP with the same design included
the EQ-5D questionnaire to measure utilities of patients with chronic pain treated
with either tapentadol PR, oxycodone CR or placebo. Utilities were obtained at
baseline and endpoint (15 weeks). An analysis was performed to explore how
EQ-5D distinguished among various health states. RESULTS: Mean utility of all
patients treated with tapentadol PR (N978) increased from 0.42 at baseline to 0.60
at endpoint, and for patients treated with oxycodone CR (N998) from 0.43 at
baseline to 0.56 at endpoint, and for patients treated with placebo (N990) from
0.41 at baseline to 0.55 at endpoint. The increase in utility was significantly higher
(p0.001) in patients treated with tapentadol compared to those treated with oxy-
codone or placebo. Presence and severity of adverse events, as well as insufficient
pain relief substantially decreased utility values in both tapentadol and oxycodone
treatment groups. Whereas the highest utilities were seen in the groups of patients
who had30% pain improvement and patients who tolerated the treatment (0.69-
0.72), patients who withdrew due to an adverse event or due to lack of efficacy had
much lower utilities (0.40-0.51). CONCLUSIONS: EQ-5D utilities of OA and LBP pa-
tients increased significantly compared to baseline when treated with tapentadol
PR or oxycodone CR, whereby the increase was significantly higher with tapentadol
PR. Sufficient pain relief and reduction of severe treatment-related adverse events
resulted in a large beneficial impact on EQ-5D utility values. This analysis clearly
demonstrates that the EQ-5D is a useful tool to measure QoL in pain studies.
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OBJECTIVES: Compare health measurements of females with bleeding disorders
(FBD) to males with von Willebrand disease (VWD) and females in the general
population (FGP). METHODS: Subjects 12yrs of age, with VWD and FBD in the
Canadian national registry were eligible for assessment. Health status and health-
related quality of life (HRQL) were measured using the Health Utilities Index Mark
3 (HUI3). The results were compared with normative data by age and gender from
the 2002/3 Joint Canada / United States Survey of Health and from the 1991 Cana-
dian General Social Survey. Mean differences and proportions were assessed using
t-test and chi square, respectively. Differences 0.05 in mean HRQL scores and
10% for proportions were considered important. Statistical significance was set at
p0.05. RESULTS: 411 HUI3 assessments were analyzed. Among 20-79 year old
FBD, mean HRQL scores were lower (diff0.150; p0.05) than in FGP. For those45
years, FBD had lower HRQL scores (diff0.080; p0.027) than males with VWD. No
difference between males with VWD and FBD 45 years of age was observed
(p0.871). Excellent health was self-reported by 18.4% of females from the registry
compared to 22.7% (p0.05) of FGP and 29.9% (p0.02) of males with VWD. Between
FDB and FGP important differences (p0.001) in the proportion reporting disability
were observed for HUI3 attributes vision, emotion, cognition, and pain for those
45 years, and ambulation, dexterity, emotion and pain for those 45 years. Be-
tween FBD and males with VWD an important difference (p0.005) in the propor-
tion reporting disability was observed for pain. FBD have similar HRQL (0.72) to
moderate (0.73) and severe (0.71) HIV-negative haemophiliacs. CONCLUSIONS: Fe-
males with bleeding disorders have greater morbidity than females in the general
population or males with VWD.
PSY42
CHRONIC PAIN: PATIENT TREATMENT PREFERENCES - A DISCRETE CHOICE
EXPERIMENT
Mühlbacher A1, Ezernieks J2, Nübling M3
A417V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
